Many articles focus on the research progress of cancer prognosis!

In this paper, I compiled several research reports, focusing on the progress of scientists in the field of cancer prognosis research, and learning with you! Photo source: commons.wikimedia.org [1] cancer: the magic medicine will come back! Aspirin may interact with DNA methylation of cells to change the prognosis of breast cancer patients! Doi: 10.1002/cncr.32364 recently, in a research report published in the international journal Cancer, scientists from the University of North Carolina found that if they were diagnosed Women with specific DNA features in specific regions of the genome may survive longer if they take aspirin before breast cancer This study suggests that later researchers may need to further study the potential of aspirin in the prevention or treatment of breast cancer patients At present, researchers don't know why some patients benefit from special therapy, while others do not In some cases, genes may play a key role, while in other cases, chemical modification of DNA may also be crucial Chemical modification of DNA is also known as epigenetic modification, which includes DNA methylation According to researcher Tengteng Wang, we want to determine whether DNA methylation will affect the effect of aspirin in breast cancer patients In this article, we will study the effect of aspirin on breast cancer DNA methylation in tissues and circulating cells in patients' blood was analyzed, including DNA sites that control the expression of 13 breast cancer-related genes In this study, the researchers analyzed for the first time the effect of DNA methylation on the association between aspirin use and death in breast cancer patients 【2】 Modern Pathol: HPV negative cervical cancer has higher malignancy and worse prognosis! Doi: 10.1038/s41379-019-0249-1 HPV negative cervical cancer is very rare, but more aggressive The disease is more common in late stage, with more metastasis and short survival period Cervical cancer is the fourth most common cancer in the world, which is the main cause of morbidity and mortality HPV infection (especially some genotypes) is the main cause of this tumor, but in a small number of cases, HPV test is negative However, it is not clear whether these tumors represent a cancer subtype with different clinical and prognostic characteristics In this study, a team led by isglobal researchers and pathologist Jaume ordi analyzed tumors in 214 women who were diagnosed with cervical cancer between 2012 and 2015 and followed up for five years at a hospital clinic in Barcelona Through a highly sensitive molecular amplification test, the researchers found that 10% of the tumors analyzed had negative VPH DNA Women with this type of tumor are usually diagnosed at a later stage, with a higher lymph node metastasis rate, and their average survival rate is only half that of women with HPV positive tumors 【3】 Cancer cell: tumor infiltrating immune cells or can effectively predict the prognosis of cancer patients In cell's research report, scientists from the University of Edinburgh identified key changes in immune cells in cancerous tumors through research, which may help to improve the development of therapies In this paper, researchers found that a series of genes expressed at high levels in breast cancer may be related to cancer types, and relevant research results may help researchers develop diagnosis And new technologies to predict the survival status of cancer patients are also expected to study the behavioral characteristics of tumors in other common cancers Under normal circumstances, immune cells can help maintain the health of the body and lower than pathogens such as bacteria and viruses However, sometimes immune cells mistakenly regard cancer tissue as healthy tissue and promote cancer progress In this study, researchers focused on the role of immune cells in endometrial cancer and breast cancer Up to now, researchers do not know the behavior characteristics of immune cells in human cancer, which will affect the development of new cancer therapy 【4】 Nat Med: a single anti-PD-1 treatment can predict the prognosis of melanoma patients! Doi: 10.1038/s41591-019-0357-y the immune response of melanoma patients to the treatment of PD-1 will occur soon after treatment, and reactive T lymphocytes can be detected in the blood after 3 weeks But researchers don't know if this early blood based test can represent changes in the tumor microenvironment For this reason, researchers from the University of Pennsylvania and other units conducted a clinical trial of new adjuvant anti-PD-1 treatment on patients with stage III / IV melanoma It was found that a adjuvant anti-PD-1 treatment before surgery can predict the clinical treatment effect of patients with surgically resectable melanoma Relevant research results were published in the journal Nature Medicine Before the start of the experiment, the researchers assumed that the recovery of immune system in tumor tissue should be detected 3 weeks after anti-PD-1 treatment, so this response would be related to disease-free survival The researchers gave 27 patients an anti-PD-1 treatment before the operation As a result, all of them detected a rapid and strong anti-tumor reaction Eight of them even experienced a complete or major pathological response, and they were all in a tumor free state 【5】 BMC cancer: the use of anti-inflammatory drugs in surgery can improve the prognosis of cancer patients doi: 10.1186/s12885-018-4641-x the world's first clinical study (surguvant) to evaluate the improvement of the effect of anti-inflammatory drugs on the surgical treatment of colon cancer patients during surgery was recently published in BMC In the journal Cancer, the study successfully tested the effect of taurochromidine, an anti-inflammatory drug with anticancer properties The study was funded by geistlich Pharma Ag in ulsen, Switzerland, and was jointly completed by researchers from the Royal College of surgery (rcsi) of Ireland, the University of cork hospital group (cuh), the University of Mersey hospital and other institutions This surguvant study examined the relationship between inflammation and cancer recurrence during surgery The experiment randomly divided patients with colon cancer undergoing surgery into placebo group and 2% taurochromidine experimental group The results of this study show that the drug can successfully inhibit the important components of inflammatory response caused by surgery that were previously thought to promote the growth of cancer cells without sacrificing the safety of patients Photo source: jagriti pal et al [6] Clin Cancer Res: why is the prognosis of glioma so poor? Maybe it's because of the mutation! Doi: 10.1158/1078-0432.ccr-17-1901 although our understanding of glioma biology has made rapid progress, the prognosis of glioma is still poor In order to find gene mutations related to glioma, scientists from the Indian Academy of science and technology conducted whole exon sequencing (WES) on patients with glioma in India, and combined it with TCGA data As a result, an important signal pathway related to glioma was found Relevant research results were published in the Journal of clinical cancer research The researchers compared Wes with TCGA data in 42 patients with astrocytoma At the same time, they conducted a comprehensive analysis of gene mutations in Indian patient data and TCGA data to find the signal pathway of glioma related mutations The researchers analyzed the function of calcitonin receptor (CALCR) using patients derived glioma stem cell like cells, glioma cell lines and mouse transplantation models 【7】 PNAs: discovery of potential target for treatment and prognosis of malignant brain tumors doi: 10.1073/pnas.1609758114 scientists from the National University of Singapore, Institute of cancer Sciences (CSI) found that protein BCL6 may be a marker for predicting the prognosis of patients with glioblastoma multiforme (GBM), which is the most malignant tumor in brain tumors, this is by CSI independent research institute H The study led by Professor Phillip koeffler found that the survival rate of GBM patients with low bccl6 expression was higher than that of GBM patients with high bccl6 expression This study also suggests that BCL6 protein may be a potential target for GBM treatment - controlling the expression level and activity of BCL6 may be helpful for the treatment of GBM GBM is a kind of malignant tumor, which can cause rapid proliferation and metastasis of cells in the brain, and has high tolerance to the traditional treatment This makes the treatment of GBM extremely difficult and challenging GBM patients usually survive less than 15 months after diagnosis This new study explored the role of BCL6 protein in GBM and the relationship between BCL6 and another GBM promoting gene Axl The research team found that BCL6 and its "small partner" NCoR can together increase the expression of Axl, thus promoting the progress of GBM 【8】 Cell Rep: to identify a new biomarker that can indicate the prognosis of patients with malignant ovarian cancer doi: 10.1016/j.celrep.2017.02.028 recently, in a research report published in the international journal Cell reports, researchers from the University of Toronto health network studied tumors in highly serous ovarian cancer High serous ovarian cancer is a common and lethal subtype of ovarian cancer In this paper, the researchers found that the high expression of biomarkers called CD151 in the body is directly related to the poor prognosis of patients Dr Medrano said that ovarian cancer is actually a lot of diseases By identifying CD151 and its key role in the survival of cancer cells, we hope to develop a new therapy to target CD151 in the later stage As the biomarker CD151 can be used as a marker of poor prognosis in patients with ovarian cancer, with further research in the future, researchers may have the potential to develop a clinical screening tool to help patients with individualized treatment 【9】 Ebiomedicine: identify the biomarker Shox2 doi: 10.1016/j.ebiom.2016.10.040 in a new study, researchers from the Southwest Medical Center of the University of Texas found a new biomarker of glioma, a common type of brain cancer This biomarker can help doctors determine the invasive nature of glioma and may ultimately help determine the best treatment The results were published in the Journal ebiomedicine The researchers found that high expression of a gene called Shox2 can predict poor survival in patients with moderate malignant glioma; as an independent biomarker, Shox2 expression is as effective as the currently best widely used marker called IDH mutation, the researchers said Brain and nervous system cancers affect nearly 24000 people a year, according to the National Cancer Institute In 2013, an estimated 152751 people in the United States had brain cancer and other neurological cancers The overall 5-year survival rate of these patients was 33.8% 【10】 Nat Commun: scientists have identified the genetic characteristics related to cancer prognosis doi:10.1038/ncomms13041 Recently, researchers from the University of Cambridge have identified the mechanical metabolism of patients with poor cancer prognosis in a study published in the International Journal Nature Communications